Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Supernus Pharmaceuticals Inc (NASDAQ: SUPN) closed the day trading at $33.52 down -15.67% from the previous closing price of $39.75. In other words, the price has decreased by -$15.67 from its previous closing price. On the day, 2.22 million shares were traded.
Ratios:
For a better understanding of SUPN, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.59 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 10.76. For the most recent quarter (mrq), Quick Ratio is recorded 1.98 and its Current Ratio is at 2.20. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Cantor Fitzgerald on Feb-20-25, Downgraded its rating to Neutral and sets its target price to $36 from $57 previously.
On January 06, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $57.
Piper Sandler Downgraded its Overweight to Neutral on September 11, 2024, whereas the target price for the stock was revised from $41 to $36.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 04 ’25 when Bhatt Padmanabh P. sold 9,477 shares for $39.70 per share. The transaction valued at 376,237 led to the insider holds 10,149 shares of the business.
Bhatt Padmanabh P. sold 2,573 shares of SUPN for $101,942 on Jan 27 ’25. The Sr. VP of IP, CSO now owns 10,149 shares after completing the transaction at $39.62 per share. On Jan 28 ’25, another insider, Bhatt Padmanabh P., who serves as the Sr. VP of IP, CSO of the company, sold 700 shares for $39.62 each. As a result, the insider received 27,734 and left with 10,149 shares of the company.
Valuation Measures:
As of this moment, Supernus’s Price-to-Earnings (P/E) ratio for their current fiscal year is 31.38, and their Forward P/E ratio for the next fiscal year is 17.40. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 142.65. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.84 while its Price-to-Book (P/B) ratio in mrq is 1.84.
Stock Price History:
Over the past 52 weeks, SUPN has reached a high of $40.28, while it has fallen to a 52-week low of $25.53. The 50-Day Moving Average of the stock is -10.69%, while the 200-Day Moving Average is calculated to be 1.75%.
Shares Statistics:
A total of 55.22M shares are outstanding, with a floating share count of 52.82M. Insiders hold about 4.35% of the company’s shares, while institutions hold 109.75% stake in the company.
Earnings Estimates
The current rating of Supernus Pharmaceuticals Inc (SUPN) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $0.41, with high estimates of $0.52 and low estimates of $0.33.
Analysts are recommending an EPS of between $2.95 and $2.83 for the fiscal current year, implying an average EPS of $2.87. EPS for the following year is $1.93, with 3.0 analysts recommending between $2.05 and $1.73.
Revenue Estimates
5 analysts predict $155.25M in revenue for the current quarter. It ranges from a high estimate of $158.9M to a low estimate of $152.9M. As of the current estimate, Supernus Pharmaceuticals Inc’s year-ago sales were $164.31MFor the next quarter, 5 analysts are estimating revenue of $144.2M. There is a high estimate of $148.3M for the next quarter, whereas the lowest estimate is $140.7M.
A total of 5 analysts have provided revenue estimates for SUPN’s current fiscal year. The highest revenue estimate was $646.5M, while the lowest revenue estimate was $640.5M, resulting in an average revenue estimate of $642.9M. In the same quarter a year ago, actual revenue was $607.52MBased on 5 analysts’ estimates, the company’s revenue will be $622.27M in the next fiscal year. The high estimate is $641.5M and the low estimate is $612.6M.
